SNMMI 2023 Annual Meeting
SNMMI 2023 Kidney Cancer
- SNMMI 2023: Zirconium-Labelled Girentuximab (89Zr-TLX250-CDx) PET/CT Imaging for Non-Invasive Diagnosis of Clear Cell Renal Cell Carcinoma: Results from the UCLA Cohort of the ZIRCON Trial
- SNMMI 2023: 89Zr-DFO-Girentuximab PET/CT Imaging Can Accurately Detect Clear Cell Renal Cell Carcinoma Primary and Secondary Lesions in Patients with Renal Masses at Conventional Imaging, Results from ZIRCON Phase 3 Study
- SNMMI 2023: PET Evaluation of Changes in c-MET Expression in Metastatic Renal Cell Carcinoma Under Therapy with Cabozantinib
- SNMMI 2023: Comparison of 68Ga-PSMA and 18F-FDG PET/CT in Metastatic Workup of Renal Cell Carcinoma (RCC)
- SNMMI 2023: Early Response Assessment to Tyrosine Kinase Inhibitors in Metastatic Clear Cell Cancer Using 68Ga-PSMA-11 PET and CECT: A Comparison Study
SNMMI 2023 Prostate Cancer
- SNMMI 2023: 68Ga-PSMA PET/CT-Based Multivariate Model for Highly Accurate and Noninvasive Diagnosis of Clinically Significant Prostate Cancer in the PSA Gray Zone
- SNMMI 2023: PSMA PET Prognostic Value for Outcome of Pre-Chemotherapy Post-ARSI CRPC Patients: A Single Center Retrospective Analysis
- SNMMI 2023: Intraindividual Comparison of [68Ga]Ga-RM2 and [68Ga]Ga-PSMA PET/CT in Patients with mCRPC in a Theranostic Setting
- SNMMI 2023: Tumour-to-Kidney Ratio on Pre-Therapeutic PSMA-PET-CT May Be Predictive of the Response [Of Lymphatic and Bone Metastases] to Therapy in mCRPC
- SNMMI 2023: Personalized PSMA-Directed Molecular RT with Identification of Favorable Genomic and Post-Therapeutic Radiomic Parameters: A Real-World Experience Post-FDA-Approval of Lu-177 PSMA-617 from a Single Comprehensive U.S. Theranostic Center